- DESCRIPTION
- TABLE OF CONTENTS
- METHODOLOGY
- DOWNLOAD PDF
Pharmaceutical Manufacturing Software Market by Offering (AI-Integrated), Type (MES, SCADA, Quality Compliance, EPR, Track & Trace), Application (Biologics, Vaccine), End User (Pharma, Biotech, CDMO), Trend, Growth, Market Share - Global Forecast to 2030
USD 5.52 BN
MARKET SIZE, 2030
CAGR 10.1%
(2025-2030)
370
REPORT PAGES
450
MARKET TABLES
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global Pharmaceutical Manufacturing Software market, valued at US$3.10 billion in 2024, stood at US$3.41 billion in 2025 and is projected to advance at a resilient CAGR of 10.1% from 2025 to 2030, culminating in a forecasted valuation of US$5.52 billion by the end of the period. The development is largely predetermined by the rise in regulatory compliance and the need to use digital and automated manufacturing solutions, the necessity to provide data integrity and traceability, and the increased need to produce pharmaceuticals worldwide. Additionally, the transition to smart factories, cloud-based platforms that are validated and additional outsourcing to CMOs and CDMOs is further stimulating market adoption.
KEY TAKEAWAYS
-
BY REGION
The North American pharmaceutical manufacturing software market accounted for a 36.0% revenue share in 2024.
-
BY OFFERING
By offering, the services segment is expected to register the highest CAGR of 11.0%.
-
BY SOFTWARE TYPE
By software type, the manufacturing operations & control software segment is projected to grow at the fastest rate from 2025 to 2030.
-
BY APPLICATIONS
By applications, the small molecules segment is expected to dominate the market.
-
BY END USER
By end user, the pharmaceutical & biotechnology companies accounted for the largest share of 68.0% in 2024.
-
COMPETITIVE LANDSCAPE
SAP SE, Dassault Systèmes, and Emerson Electric Co. are key leaders in the global pharmaceutical manufacturing software market, recognized for their extensive product portfolios, robust data integration capabilities, and strong presence across healthcare ecosystems.
The pharmaceutical manufacturing software market is rapidly growing, as investments in digital manufacturing grow, and the emphasis on regulatory compliance, data integrity, and operational efficiency in the pharmaceutical production increases in the US and EU. The development of MES, QMS, LIMS, automation, and real-time analytics enhances the traceability of batches, quality, planning of production, and the entire performance of the manufacturing process. Moreover, the growing trend in strategic collaboration among pharmaceutical companies, software providers, and automation vendors is driving innovation at a faster pace and creating more integrated, scalable, and compliant manufacturing environments.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on the business of consumers in the pharmaceutical manufacturing software market is based on evolving regulatory needs, the rising complexity of manufacturing, and continuous digital transformation initiatives. The primary end users are pharmaceutical manufacturers, biopharma companies, and CMOs/CDMOs, whose operational and compliance requirements are the catalysts for the software adoption. The shifts in trends or interruptions like the increasing demands for MES, QMS, electronic batch records, real-time monitoring, and automation directly impact the manufacturing efficiency, quality results, and cost optimization, affecting the revenue growth and competitiveness of the pharmaceutical manufacturing software vendors.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Drivers
Impact
Level
-
Stronger regulatory enforcement & need for data integrity
-
Digital transformation/Industry 4.0 adoption (AI, IoT, digital twins)
RESTRAINTS
Impact
Level
-
High validation, compliance burden, and legacy infrastructure complexity
-
Data security & privacy concerns
OPPORTUNITIES
Impact
Level
-
Growing demand for biologics, personalized medicine, and contract manufacturing
-
Adoption of AI-driven analytics and validated cloud-based platforms
CHALLENGES
Impact
Level
-
Maintaining GxP compliance during digital transformation
-
Achieving interoperability across diverse manufacturing systems
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Increased regulatory compliance and the increasing demands for data integrity are major forces behind the pharmaceutical manufacturing software market. The stricter compliance requirements regarding Good Manufacturing Practice (GMP), electronic recordings, and audit readiness suggested by regulatory bodies in large areas are forcing pharmaceutical manufacturers towards the use of advanced digital solutions. The software manufacturing will contribute to better focus on gathering the right data, traceability, and real-time monitoring along with production processes, and help to avoid mistakes and failure to comply. Also, the emerging concern about the integrity of data, verification, and safe documentation is enhancing the transition of manual systems to automated manufacturing processes with the use of software.
Stringent validation rules, regulatory requirements, and the complexity associated with poor-quality legacy infrastructure are major restraints for the pharmaceutical manufacturing software market. The implementation process associated with the pharmaceutical manufacturing process is quite expensive and time-consuming, as pharma manufacturers need to complete a considerable amount of system validation, documentation, and auditing to meet strict regulatory requirements. The integration of new software with the existing legacy infrastructure system can be challenging, as it creates disruption in the smooth functionality associated with the system.
The increased demand for biologics and personalized medicine, as well as the contract manufacturing, is a major opportunity for the pharmaceutical manufacturing software market. Such complicated and expensive treatments demand a higher level of control of the process, real-time monitoring of the data, and adherence to quality standards, which promotes the necessity of highly developed manufacturing software. CMOs also tend to implement digital solutions that help to manage the multi-client operations, provide the appropriate traceability, and uphold the regulatory procedures. With the increasing specialization and flexibility of pharmaceutical production, software-based manufacturing systems are now needed to facilitate scalability and operational efficiency.
Maintaining GxP compliance in digital transformation is one of the most significant issues the pharmaceutical manufacturing software market faces. With the transition of manufacturers to high-tech digital systems, paper-based and old systems, manufacturers have to guarantee that all procedures follow the high standards of GxP concerning data integrity, system validation, and audit readiness. Change management that does not disturb the controlled production settings is complicated and risky. Any compliance lapses at the time of system upgrade or integration may result in regulatory fines, delay in production, or expensive corrective actions.
PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Industrial automation and manufacturing execution systems for pharmaceutical production environments. | Increased process reliability, improved throughput, and reduced operational risk. |
|
|
Quality management and manufacturing software supporting document control, training, audits, and regulatory compliance for pharmaceutical production. | Improved compliance readiness, reduced quality risks, and faster audit and validation processes. |
|
|
Digital manufacturing and MES solutions for pharma production, equipment monitoring, and process optimization. | Enhanced operational visibility, reduced downtime, and improved manufacturing accuracy. |
|
|
Enterprise software for pharmaceutical manufacturing integrating production planning, supply chain, and quality management. | Better coordination across operations, improved traceability, and increased manufacturing efficiency. |
|
|
Cloud-based quality, manufacturing, and regulatory software for life sciences organizations. | Faster compliance processes, improved collaboration, and streamlined manufacturing documentation. |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
SAP SE (Germany), Dassault Systèmes (France), Emerson Electric Co. (US), and Rockwell Automation (US) are the leading providers of the software market ecosystem in the pharmaceutical manufacturing industry and offer solutions such as MES, ERP, QMS, digital twins, and automation platforms to manufacture pharmaceuticals. To enhance efficiency, guarantee regulatory compliance, and enhance product quality, these companies employ real-time analytics and proven digital workflows. These solutions are being adopted by end users such as pharma manufacturers, biopharma companies, and CMOs/CDMOs to reduce operational risk, ensure integrity of data, and optimize production processes, and continuous cooperation between vendors and manufacturers leads to the transition to smart pharma factories.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Based on offering, the pharmaceutical manufacturing software market includes services and software. The software segment accounted for the largest share. This is due to the growing use of MES, QMS, LIMS, and ERP solutions to maintain regulatory compliance, data integrity, and real-time visibility throughout manufacturing operations. There is also an increase in demand for automation, electronic batch records, and analytics-driven production optimization, which also enhances the leadership of the software segment.
Based on the software type, the manufacturing operations and control software segment holds a significant market share. This is because of the growing demand for real-time monitoring in production, electronically prepared batch records, automating processes, and regulatory compliance that will help pharmaceutical manufacturing companies to enhance the efficiency of the operations, quality of the products, and integrity of the data in the different manufacturing plants.
Based on applications, the small molecules segment contributed significantly to the pharmaceutical manufacturing software market. This growth is driven by the large quantity of small-molecule drug synthesis, long-established manufacturing workflows, and the widespread use of manufacturing execution and quality management software as a guarantee of efficiency, consistency, and compliance with regulations throughout the large-scale manufacturing processes. Moreover, the existence of mature supply chains and the continuous need for generics also contribute to software adoption in this market.
Based on the end users, the market is segmented into pharmaceutical & biotechnology companies and contract development and manufacturing organizations (CDMOs). Pharmaceutical and biotechnology companies hold a significant share of this market. That is because of their extensive manufacturing activities, high investment potential in digital and automated processes, and their concern with regulatory compliance, quality control, and data integrity. Also, branded and generic drugs production in-house leads to long-term profits in the manufacturing and quality management software business.
REGION
Asia Pacific to be fastest-growing region in global pharmaceutical manufacturing software market during forecast period
The Asia Pacific is expected to be the fastest-growing region in the pharmaceutical manufacturing software market during the forecast period. This development is driven by the expansion of pharmaceutical production plants, increasing investments in digital and automated production models, and the easing of regulatory constraints in China, India, and Japan. Additionally, the quick development of generic drug production, the increased role of CMOs and CDMOs, and favorable government support for smart manufacturing and digitalization are increasing the pace of uptake of high-end pharma manufacturing software in the region.
PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET: COMPANY EVALUATION MATRIX
Rockwell Automation (Star) is among the market leaders in the pharmaceutical manufacturing software industry because of its robust industrial automation knowledge, full-fledged MES and control hardware, and pervasiveness in the manufacturing processes with a high level of compliance and operational idealism. TraceLink Inc. (Emerging Leader) is essential as it facilitates cloud-based, secure digital solutions that facilitate end-to-end traceability, regulatory compliance, and real-time data sharing in the pharmaceutical manufacturing and supply chains.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Rockwell Automation (US)
- Körber AG (Germany)
- Siemens Digital Industries (Germany)
- Veeva Systems (US)
- IQVIA (US)
- SAP SE (Germany)
- Dassault Systèmes (France)
- Emerson Electric Co. (US)
- Honeywell International Inc. (US)
- ABB (Switzerland)
- Merative (US)
- TraceLink Inc. (US)
- Oracle (US)
- IBM (US)
- MasterControl (US)
- eschbach (Germany)
- Microsoft (US)
- BatchMaster Software Pvt. Ltd. (US)
- Sage Group Plc (UK)
- Aptean (US)
- Benchling (US)
- Bigfinite Inc., dba Aizon (US)
- Tulip Interfaces, Inc. (US)
- Apprentice (US)
- Inductive Automation, LLC. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 3.10 Billion |
| Market Forecast in 2030 (Value) | USD 5.52 Billion |
| Growth Rate | CAGR of 10.1% from 2025-2030 |
| Years Considered | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Parent & Related Segment Reports |
Healthcare IT Market Medical Coding Market Asia Pacific Healthcare IT Market US Healthcare IT Market Europe Healthcare IT Market |
WHAT IS IN IT FOR YOU: PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Competitive Landscape Mapping | Profiles of the most popular pharma manufacturing software (e.g., SAP, Siemens, Rockwell Automation, Oracle, Dassault Systèmes) of MES, QMS, ERP, LIMS, and serialization. | Facilitates benchmarking of vendors, determines differentiation between compliance and automation facilities, and aids in partnership and vendor selection. |
| Market Entry & Growth Strategy | Dissection of adoption in branded and generic pharma, CMOs/CDMOs, geographical manufacturing centers, and digital transformation (Industry 4.0). | Eliminates market-entry risk, helps prioritize high-growth customer segments, and helps with scalable commercialization strategies. |
| Regulatory & Operational Risk Analysis | Risk assessment of compliance requirements such as FDA 21 CFR Part 11, GMP, GAMP 5, data integrity (ALCOA+), and global serialization requirements. | Enhances regulatory preparedness, lessens audit and compliance risk, and boosts plausibility with regulators and manufacturers. |
| Technology Adoption Trends | The understanding of adoption of cloud-enabled MES, Al driven quality analytics, digital twins, predictive maintenance, and end-to-end manufacturing visibility. | Informs the product roadmap, enhances competitive positioning, and justifies dedicated investment in state-of-the-art manufacturing software. |
RECENT DEVELOPMENTS
- May 2025 : Rockwell Automation launched the modified version of the manufacturing execution system known as FactoryTalk Pharma Suite 12.00, which is aimed at regulated manufacturing of pharmaceutical and biopharmaceutical products. Its release is aimed at making systems easier to manage, providing deployments that are both secure and scalable, as well as enhancing the production efficiency of compliance-oriented environments.
- March 2025 : Emerson acquired all the outstanding shares of Aspen Technology, Inc., which now operates as a subsidiary of Emerson. The purchase enriched Emerson's software and digital strengths and broadened its portfolio of sophisticated process optimization and industrial software in regulated industries, such as pharmaceutical manufacturing.
- March 2025 : Dassault Systèmes and its Medidata brand announced a strategic investment in Click Therapeutics through a Series C round. The investment enhances co-innovation between the companies to create further digital therapeutics capacity and utilize real-world data, increasing patient interaction and insights on information across the life sciences ecosystem.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
TITLE
PAGE NO
1
INTRODUCTION
15
2
EXECUTIVE SUMMARY
3
PREMIUM INSIGHTS
4
MARKET OVERVIEW
4.1
INTRODUCTION
4.2
MARKET DYNAMICS
4.2.1
DRIVERS
4.2.2
RESTRAINTS
4.2.3
OPPORTUNITIES
4.2.4
CHALLENGES
4.3
UNMET NEEDS AND WHITE SPACES
4.4
INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.5
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
5.1
PORTER’S FIVE FORCES ANALYSIS
5.2
MACROECONOMICS INDICATORS
5.2.1
INTRODUCTION
5.2.2
GDP TRENDS AND FORECAST
5.2.3
TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
5.3
VALUE CHAIN ANALYSIS
5.4
ECOSYSTEM ANALYSIS
5.5
PRICING ANALYSIS
5.5.1
INDICATIVE PRICE FOR PHARMACEUTICAL MANUFACTURING SOFTWARE, BY KEY PLAYERS (2024)
5.5.2
INDICATIVE PRICE FOR PHARMACEUTICAL MANUFACTURING SOFTWARE, BY REGION (2024)
5.6
KEY CONFERENCES AND EVENTS, 2026–2027
5.7
TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8
INVESTMENT AND FUNDING SCENARIO
5.9
CASE STUDY ANALYSIS
5.10
IMPACT OF 2025 US TARIFF – PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET
5.10.1
INTRODUCTION
5.10.2
KEY TARIFF RATES
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON COUNTRIES/REGIONS
5.10.4.1
US
5.10.4.2
EUROPE
5.10.4.3
APAC
5.10.5
IMPACT ON END-USE INDUSTRIES
6
TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.4
PATENT ANALYSIS
6.5
FUTURE APPLICATIONS
6.6
IMPACT OF AI/GEN AI ON PHARMACEUTICAL MANUFACTURING SOFTWARE
6.6.1
TOP USE CASES AND MARKET POTENTIAL
6.6.2
BEST PRACTICES IN PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET
6.6.3
CASE STUDIES OF AI IMPLEMENTATION IN THE PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET
6.6.4
INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
6.6.5
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN THE MARKET
7
REGULATORY LANDSCAPE
7.1
REGIONAL REGULATIONS AND COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.2
INDUSTRY STANDARDS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
9
PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET, BY OFFERING (MARKET SIZE & FORECAST TO 2030)
9.1
INTRODUCTION
9.2
SOFTWARE
9.2.1
AI-INTEGRATED
9.2.2
CONVENTIONAL
9.3
SERVICES
9.3.1
IMPLEMENTATION & INTEGRATION
9.3.2
CUSTOMIZATION
9.3.3
TRAINING & EDUCATION
9.3.4
SUPPORT & MAINTENENACE
9.3.5
OTHERS (COMPLIANCE, SECURITTY SERVICES, DIGITAL TRANSFORMATION, DOCUMENTATION, ETC.)
10
PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET, BY SOFTWARE TYPE (MARKET SIZE & FORECAST TO 2030)
10.1
INTRODUCTION
10.2
MANUFACTURING OPERATIONS & CONTROL SOFTWARE
10.2.1
SCADA (SUPERVISORY CONTROL & DATA ACQUISTION)
10.2.2
MES (MANUFACTURING & EXECUTION SYSTEMS)
10.2.3
BATCH CONTROL SOFTWARE
10.2.4
DCS (DISTRIBUTED CONTROL SYSTEM)
10.3
QUALITY COMPLIANCE & VALIADTAION
10.4
PLANNING SCHEDULING & SUPPLY CHAIN
10.4.1
ERP (ENTERPRISE RESOUCE PLANNING)
10.4.2
APS (ADVANCED PLANNING & SCHEDULING)
10.4.3
INVENTORY MANAGEMENT
10.5
EQUIPMENT & ASSET MAINTENANCE SOFTWARE
10.6
PROCESS ANALYTICS & OPTIMIZATION SOFTWARE
10.7
SERIALIZATION, PACKAGING & TRACK & TRACE
10.8
OTHERS (ENVIRONMENTAL SAFETY, IOT INTEGRATIONS, ENABLERS, CALLIBRATION TOOLS, ETC.)
11
PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2030)
11.1
INTRODUCTION
11.2
SMALL MOLECULES
11.3
BIOLOGICS (MONOCLONAL ANTIBODIES, RECOMBINENT PROTEINS, ETC.)
11.4
VACCINES
11.5
CELL & GENE THERAPY
11.6
OTHERS (RECOMBINENT PRODUCTS, PLASMA DERIVEDTHERAPIES,ETC.)
12
PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET, BY END USER (MARKET SIZE & FORECAST TO 2030)
12.1
INTRODUCTION
12.2
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.2.1
LARGE PHARMA COMPANIES
12.2.2
MID-SIZED PHARMA COMPANIES
12.2.3
SMALL PHARMA COMPANIES
12.3
CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS)
13
PHARMACEUTICAL MANUFACTURING SOFTWARE MARKET, BY REGION (MARKET SIZE & FORECAST TO 2030)
13.1
INTRODUCTION
13.2
NORTH AMERICA
13.2.1
US
13.2.2
CANADA
13.3
EUROPE
13.3.1
GERMANY
13.3.2
FRANCE
13.3.3
UK
13.3.4
ITALY
13.3.5
SPAIN
13.3.6
REST OF EUROPE
13.4
ASIA PACIFIC
13.4.1
CHINA
13.4.2
JAPAN
13.4.3
INDIA
13.4.4
AUSTRALIA
13.4.5
SOUTH KOREA
13.4.6
REST OF ASIA PACIFIC
13.5
LATIN AMERICA
13.5.1
BRAZIL
13.5.2
MEXICO
13.5.3
REST OF LATIN AMERICA
13.6
MIDDLE EAST & AFRICA
13.6.1
GCC COUNTRIES
13.6.1.1
SAUDI ARABIA
13.6.1.2
UAE
13.6.1.3
REST OF GCC
13.6.2
SOUTH AFRICA
13.6.3
REST OF MIDDLE EAST & AFRICA
14
COMPETITIVE LANDSCAPE
STRATEGIC ASSESSMENT OF LEADING PLAYERS, MARKET SHARE, REVENUE ANALYSIS, COMPANY POSITIONING, AND COMPETITIVE BENCHMARKS INFLUENCING MARKET POTENTIAL
14.1
OVERVIEW
14.2
KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN
14.3
REVENUE ANALYSIS (2020-2024)
14.4
MARKET SHARE ANALYSIS (2024)
14.5
BRAND/SOFTWARE COMPARATIVE ANALYSIS
14.6
COMPANY EVALUATION MATRIX: KEY PLAYERS,
14.6.1
STARS
14.6.2
EMERGING LEADERS
14.6.3
PERVASIVE PLAYERS
14.6.4
PARTICIPANTS
14.6.5
COMPANY FOOTPRINT: KEY PLAYERS,
14.6.5.1
COMPANY FOOTPRINT
14.6.5.2
REGION FOOTPRINT
14.6.5.3
OFFERING FOOTPRINT
14.6.5.4
SOFTWARE TYPE FOOTPRINT
14.6.5.5
APPLICATION FOOTPRINT
14.6.5.6
END USER FOOTPRINT
14.7
COMPANY EVAULATION MATRIX: STARTUPS/SMES,
14.7.1
PROGRESSIVE COMPANIES
14.7.2
DYNAMIC COMPANIES
14.7.3
RESPONSIVE COMPANIES
14.7.4
STARTING BLOCKS
14.7.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
14.7.5.1
DETAILED LIST OF KEY STARTUPS/SMES
14.7.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
14.8
COMPANY VALUATION AND FINANCIAL METRICS
14.9
COMPETITIVE SCENARIOS
14.9.1
PRODUCT LAUNCHES & UPGRADES
14.9.2
DEALS
14.9.3
EXPANSIONS
14.9.4
OTHERS
15
COMPANY PROFILES
IN-DEPTH REVIEW OF COMPANIES, PRODUCTS, SERVICES, RECENT INITIATIVES, AND POSITIONING STRATEGIES IN THE MARKET LANDSCAPE
15.1
KEY PLAYERS
15.1.1
SAP SE
15.1.1.1
BUSINESS OVERVIEW
15.1.1.2
PRODUCTS/SOLUTIONS/SERVICES OFFERED
15.1.1.3
MNM VIEW
15.1.1.3.1
KEY STRENGTHS/RIGHT TO WIN
15.1.1.3.2
STRATEGIC CHOICES
15.1.1.3.3
WEAKNESS/COMPETITIVE THREATS
15.1.2
DASSAULT SYSTÈMES
15.1.3
EMERSON ELECTRIC CO.
15.1.4
ROCKWELL AUTOMATION
15.1.5
HONEYWELL INTERNATIONAL INC.
15.1.6
ABB
15.1.7
MERATIVE
15.1.8
KÖRBER AG
15.1.9
TRACELINK INC.
15.1.10
ORACLE
15.1.11
IBM
15.1.12
MASTERCONTROL
15.1.13
VEEVA SYSTEMS
15.1.14
ESCHBACH
15.1.15
MICROSOFT
15.1.16
IQVIA
15.1.17
SIEMENS DIGITAL INDUSTRIES
15.1.18
BATCHMASTER SOFTWARE PVT. LTD.
15.1.19
SAGE GROUP PLC.
15.1.20
APTEAN
15.2
OTHER PLAYERS
15.2.1
BENCHLING
15.2.2
AIZON
15.2.3
TULIP INTERFACES
15.2.4
APPERENTICE.IO
15.2.5
INDUCTIVE AUTOMATION
16
RESEARCH METHODOLOGY
16.1
RESEARCH DATA
16.1.1
SECONDARY DATA
16.1.1.1
KEY DATA FROM SECONDARY SOURCES
16.1.2
PRIMARY DATA
16.1.2.1
KEY DATA FROM PRIMARY SOURCES
16.1.2.2
KEY PRIMARY PARTICIPANTS
16.1.2.3
BREAKDOWN OF PRIMARY INTERVIEWS
16.1.2.4
KEY INDUSTRY INSIGHTS
16.2
MARKET SIZE ESTIMATION
16.2.1
BOTTOM-UP APPROACH
16.2.2
TOP-DOWN APPROACH
16.2.3
BASE NUMBER CALCULATION
16.3
MARKET FORECAST APPROACH
16.3.1
SUPPLY SIDE
16.3.2
DEMAND SIDE
16.4
DATA TRIANGULATION
16.5
FACTOR ANALYSIS
16.6
RESEARCH ASSUMPTIONS
16.7
RESEARCH LIMITATIONS AND RISK ASSESSMENT
17
APPENDIX
17.1
DISCUSSION GUIDE
17.2
KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
17.3
CUSTOMIZATION OPTIONS
17.4
RELATED REPORTS
17.5
AUTHOR DETAILS
Methodology
The study involved major activities in estimating the current market size for the pharmaceutical manufacturing software market. Exhaustive secondary research was done to collect information on the industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the pharmaceutical manufacturing software market.
Secondary Research
The market for the companies offering pharmaceutical manufacturing software is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry's value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.
Primary Research
Extensive primary research has been conducted after understanding and analyzing the current scenario of the pharmaceutical manufacturing software market through secondary research. Several primary interviews have been conducted with the key opinion leaders from the demand and supply sides across four main regions—North America, Europe, Asia Pacific, and the Rest of World. Approximately 30% of the primary interviews were conducted with the demand-side respondents, while approximately 70% were conducted with the supply-side respondents. The primary data has been collected through questionnaires, emails, and telephone interviews.
After interacting with industry experts, brief sessions were conducted with highly experienced independent consultants to reinforce the findings from our primary. This, along with the in-house subject matter experts’ opinions, has led us to the findings as described in the remainder of this report. The breakdown of primary respondents is as follows:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches wete used to estimate and validate the total size of the pharmaceutical manufacturing software market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Pharmaceutical Manufacturing Software Market : Top-Down and Bottom-Up Approach
Data Triangulation
After arriving at the overall market size using the market size estimation processes as explained above, the market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from the demand and supply sides.
Market Definition
Pharmaceutical manufacturing software refers to the machinery and instruments used to manufacture pharmaceutical products. Various equipment are used to produce pharmaceutical drugs and solutions, including mixers and blenders, extruders, milling equipment, tablet compression presses, inspection equipment, and packaging machines.
Key Stakeholders
- End users
- Government bodies, venture capitalists, and private equity firms
- Pharmaceutical manufacturing software manufacturers
- Pharmaceutical manufacturing software industry associations
- Professional service/solution providers
- Research institutions and organizations
- Standards organizations and regulatory authorities
- System integrators
- Technology consultants
Report Objectives
- To describe and forecast the pharmaceutical manufacturing software market, in terms of value, based on equipment type and end-product type
- To forecast the size of the pharmaceutical manufacturing software market in terms of volume
- To forecast the market size, in terms of value, for four main regions—North America, Europe, Asia Pacific, and the RoW (Rest of the World)
- To provide detailed information regarding drivers, restraints, opportunities, and challenges influencing the market growth
- To provide a detailed overview of the value chain of the pharmaceutical manufacturing software ecosystem
- To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the total market
- To analyze the opportunities for stakeholders and details of the competitive landscape of the market
- To strategically profile the key players and comprehensively analyze their market positions in terms of ranking and core competencies2
- To analyze the major growth strategies implemented by key market players, such as agreements, acquisitions, product launches, expansions, and partnerships
- To study the impact of AI on the market under study, along with macroeconomic outlook for each region
Available Customizations
With the given market data, MarketsandMarkets offers customizations according to the specific requirements of companies. The following customization options are available for the report:
- Detailed analysis and profiling of additional market players based on various blocks of the supply chain
⚡ Growth Signals
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Pharmaceutical Manufacturing Software Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Company
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Company
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnostics
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
Still Researching the
Pharmaceutical Manufacturing Software Ecosystem?
See the competitors, opportunities, and growth signals shaping it - instantly.
Generate 15+ consulting-grade strategic insights tailored to your growth question.
